Development and validation of method for glucosaminylmuramyl dipeptide determining in aqueous solutions by high-performance liquid chromatography

• Kursakov S.V.
• Kuznetsova E.G.
• Kuryleva O.M.
• Salomatina L.A.
• Svetlana V. Guryanova
• Borisova O.Yu.
• Georgii O. Gudima
• Sevastyanov V.I.

Abstract

Introduction. For the determination of peptide-based drugs the reverse phase HPLC method with a gradient elution mode is widely used. Among the published works no validated methods suitable for the study of new dosage forms of glucosaminyl muramyl dipeptide (GMDP) were found. Due to the significant drawbacks of gradient elution, it is recommended to avoid the use of a gradient when developing methods for HPLC analysis, preferring isocratic elution to it.

The aim of the study is the development and validation of a method for the quantitative determination of glucosaminyl muramyl dipeptide in aqueous solutions using the isocratic elution regimen, which can be used in the development of new dosage forms of GMDP.

Material and methods. Quantitative determination of GMDP in solutions was carried out by reverse phase HPLC in isocratic mode on a Mediterranea Sea18 15 x 0.4 cm, 5 pm column using an eluent of the composition acetonitrile: 25 mM phosphate buffer solution (3:97), pH 7.3; a flow rate of 0.7 ml/min; a detector wavelength of 200 nm; and a column thermostat temperature of 25 °C.

Results. The developed technique was validated by the following characteristics: specificity, linearity, correctness, repeatability (convergence), intermediate (laboratory) precision, analytical area, suitability of the chromatographic system. The technique has been successfully tested on laboratory samples of transdermal therapeutic systems containing GMDP.

Conclusion. A method has been developed for the quantitative determination of GMDP in aqueous solutions by reverse phase HPLC with isocratic elution. The suitability of the method is confirmed by the compliance of the main validation characteristics with the acceptance criteria. The confirmed analytical range of the method was 0.5-50 pg/ml. The technique can be used in the analytical part of preclinical studies of new dosage forms of GMDP.

Keywords:glucosaminylmuramyldipeptide; aqueous solutions; reverse phase HPLC; isocratic elution mode

References

1. Philpott D.J., Sorbara M.T., Robertson S.J., Croitoru K., Girardin S.E. NOD proteins: regulators of inflammation in health and disease. Nat. Rev. Immunol. 2014; 14 (1): 9–23. DOI: 10.1038/nri3565.

2. Fritz J.H., Ferrero R.L., Philpott D.J., Girardin S.E. Nod-like proteins in immunity, inflammation and disease. Nat. Immunol. 2006; 7 (12): 1250–7.

3. Caruso R., Warner N., Inohara N., Núñez G. Immunity. NOD1 and NOD2: signaling, host defense, and inflammatory disease. Immunity. 2014; 41 (6): 898–908.

4. Manapova E.R., Fazylov V.Kh., Guryanova S.V. Cytopenias and their correction in antiviral therapy of chronic hepatitis C in patients with genotype 1. Voprosy virusologii. 2017; 62 (4): 174–8. (in Russian)

5. Kolesnikova N.V., Kozlov I.G., Guryanova S.V., Kokov E.A., Andronova T.M. Clinical and immunological effectiveness and prospects of using muramyldipeptides in the treatment of atopic diseases. Meditsinskaya immunologiya. 2016; 18 (1): 15–20. (in Russian)

6. Kozlov I.G., Voronina E.V., Valyakina T.I., SimonovaM.A., Guryanova S.V., Meshcheryakova E.A., AndronovaT.M. Дycopide in tumor immunotherapy: a review ofexperimental studies (literature review). Voprosygematologii/oncologii i immunopatologii v pediatrii. 2011; 10 (2): 32–8. (in Russian)

7. Luss L.V. Secondary immunodeficiency States inchildren. The Clinician's view on the appointment of immunomodulatory therapy. Allergologiya i immunologiya v pediatrii. 2018; 55 (4): 4–18. (in Russian)

8. Guryanova S., Udzhukhu V., Kubylinsky A. Pathogenetic therapy of psoriasis by muramyl peptide. Front. Immunol. 2019; 10: 1275–83. DOI: 10.3389/fimmu.2019.01275.

9. Guryanova S.V., Kozlov I. G., Meshcheryakova E.A., Alekseeva L.G., Andronova T.M. Glucosaminylmurildipeptide normalizes the balance ofTS1/Th2 in atopic asthma. Immunologiya. 2009; 30 (5): 305–8 (in Russian)

10. Ushkalova E.A., Zyryanov S.K., Zatolokina K.E. Connection on the basis of muramyldipeptide in modern medicine: focus on glucosaminilmuramilpentapeptide. Terapevticheskiy arkhiv. 2019; 12: 12–7. (in Russian)

11. Guryanova S., Andronova T., Kozlov I. The role of NOD2 ligands muramyl peptides in chemotherapy induced cytopenia. Eur. J. Immunol. 2019; 49 (suppl 3): 1229.

12. ISBN: 978-5-9704-4378-1. Immunotherapy: A guide for physicians. In: R.M. Khaitov, R.I. Ataullakhanov, A.E. Shulzhenko (eds). Moscow: GEOTAR-Media; 2018: 768 p. ISBN: 978-5-9704-4378-1. (in Russian)

13. Khaitov R.M., Pinegin B.V., Andronova T.M. Domestic immunotropic medicines of the last generation and their application strategy. Lechashchiy vrach. 1998; 4: 46–51.(in Russian)

14. Aguilar M.-I. HPLC of peptides and proteins: basic theory and methodology. Methods Mol. Biol. 2004; 251: 3–9.

15. Mant C., Chen Y., Yan Z., Popa T., Kovacs J., Mills J., Tripet B., Hodges R. HPLC analysis and purification of peptides. Methods Mol. Biol. 2007; 386: 3–55. DOI: 10.1007/978-1-59745-430-8_1.

16. Carr D. A Guide to the Analysis and Purification of Proteins and Peptides by Reversed-Phase HPLC. Aberdeen: Advanced Chromatography Technologies, 2002: 64 p.

17. Frkanec R., Tomašić J. High performance liquid chromatography in analysis of compounds comprising the elements of bacterial peptidoglycan structure with immunological activity. J. Liq. Chromatogr. Relat. Tech. 2007; 31 (1): 107–33. DOI: 10.1080/10826070701665709.

18. Golovina T., Fattakhova G., Swiderek K., Makarov E., Bovin N., Shively J., Nesmeyanov V. Specific binding of glucosaminylmuramyl peptides to histones. FEBS Lett. 1999; 454 (12): 152–6. DOI: 10.1016/S0014-5793(99)00689-4.

19. Psylinakis E., Boneca I., Mavromatis K., Deli A., Hayhurst E., Foster S., Varum K., Bouriotisa V. Peptidoglycan N-acetylglucosamine deacetylases from Bacillus cereus, highly conserved proteins in Bacillus anthracis. J. Biol. Chem. 2005; 280 (35): 30 856–63. DOI: 10.1074/jbc.M407426200.

20. Kaydalov A.A., Utkin Yu.N., Andronova T.M., TsetlinV.I., Ivanov V.T. specific binding of muramylpeptides torat brain membranes. Bioorganicheskaya khimiya. 1987; 13 (11): 1523–9. (in Russian)

21. Golovina T.N., Sumaroka M.V., Samokhvalova L.V., Andronova T.M., Nesmeyanov V.A. Biochemical characterization of glucosaminylmuramyldipeptide binding sites of murine macrophages. FEBS Lett. 1994;356 (1): 9–12. DOI: 10.1016/0014-5793(94)01219-9.

22. Meshcheryakova E., Mineev K., Volynski P., Andronova T., Ivanov V. GMDP: unusual physico-chemical and biological properties of the anomeriс forms. J. Pept. Sci. 2015; 21 (9): 717–22. DOI: 10.1002/psc.2796.

23. Sychev K.S. Practical course of liquid chromatography. Moscow: Kokoro, 2013. (in Russian)

24. OFP1.1.0013.15. Statistical processing of chemical experiment results. State Pharmacopoeia of the Russian Federation. XIV ed. Moscow; 2018; 1: 289–318. (in Russian)

25. OFP.1.1.0012.15. Validation of analytical methods. State Pharmacopoeia of the Russian Federation. XIV ed. Moscow; 2018; 1: 276–88. (in Russian)

26. ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology. Q2(R1). Geneva, 2005: 13 p.

27. Epshteyn N.A. Assessment of the suitability (validation) of HPLC methods in pharmaceutical analysis (review). Khimiko-farmatsevticheskiy zhurnal. 2004; 38 (4): 40–56. (in Russian)

28. OFP.1.2.1.2.0001.15. Chromatography. State Pharmacopoeia of the Russian Federation. XIV ed. Moscow, 2018; 1: 845–72. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)